- Home >
- Clinicals Trials >
- TG4050.02
Retour à la liste des essais cliniquesENT/Head and Neck Cancers
TG4050.02
A randomized phase I trial in patients with newly-diagnosed, locoregionally advanced, HPV-negative, squamous cell carcinoma of the head and neck (SCCHN);evaluating a mutanome-directed immunotherapy;initiated at completion of primary treatment or at time of recurrence
- Ouvert à Paris depuis le : 13/10/2020
- Public cible : Adult
- Phase : Phase I
Description de l'essai
To evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active immunotherapy (TG4050) in patients with newly diagnosed, locoregionally advanced, HPV-negative SCCHN initiated at completion of primary treatment (Arm A) or at the time of recurrence (Arm B)
Url of the trialInvestigateur principal
